Research Progress on the Development of Hepatocyte Growth Factor/c-Met Signaling Pathway in Gastric Cancer: A Review

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2024 Aug 22

PMID 39171189

Authors

Wu-Jie Wei

Ya-Li Hong

Yi Deng

Guan-Liang Wang

Jiang-Tao Qiu

Fang Pan

Affiliations

Soon will be listed here.

Abstract

Hepatocyte growth factor (HGF) and its receptor, c-Met, play important roles in the occurrence, development, and treatment of gastric cancer (GC). This review explored the function of the HGF/c-Met signaling pathway in GC and its potential targeted therapeutic mechanisms. As one of the most common malignant tumors worldwide, GC has a complex pathogenesis and limited therapeutic options. Therefore, a thorough understanding of the molecular mechanism of GC is very important for the development of new therapeutic methods. The HGF/c-Met signaling pathway plays an important role in the proliferation, migration, and invasion of GC cells and has become a new therapeutic target. This review summarizes the current research progress on the role of HGF/c-Met in GC and discusses targeted therapeutic strategies targeting this signaling pathway, providing new ideas and directions for the treatment of GC.

References

Catenacci D, Henderson L, Xiao S, Patel P, Yauch R, Hegde P . Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2012; 1(7):573-9. PMC: 3289149. DOI: 10.1158/2159-8290.CD-11-0175. View

Seo S, Ryu M, Ryoo B, Park Y, Park Y, Na Y . Clinical significance of gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy. Chin J Cancer Res. 2019; 31(4):620-631. PMC: 6736660. DOI: 10.21147/j.issn.1000-9604.2019.04.06. View

Catenacci D, Tebbutt N, Davidenko I, Murad A, Al-Batran S, Ilson D . Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(11):1467-1482. PMC: 5898242. DOI: 10.1016/S1470-2045(17)30566-1. View

Tong G, Cheng B, Li J, Wu X, Nong Q, He L . MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells. Cancer Med. 2019; 8(16):7044-7054. PMC: 6853821. DOI: 10.1002/cam4.2542. View

Amemiya H, Kono K, Itakura J, Tang R, Takahashi A, An F . c-Met expression in gastric cancer with liver metastasis. Oncology. 2002; 63(3):286-96. DOI: 10.1159/000065477. View

Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S . Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014; 24(12):588-96. PMC: 4218879. DOI: 10.1097/FPC.0000000000000091. View

Graziano F, Catalano V, Lorenzini P, Giacomini E, Sarti D, Fiorentini G . Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy. Pharmacogenomics J. 2014; 14(5):418-23. DOI: 10.1038/tpj.2014.11. View

Wu L, Li X, Yan J . Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol. 2024; 45:101995. PMC: 11150959. DOI: 10.1016/j.tranon.2024.101995. View

Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X . NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024; 10(7):e28282. PMC: 11004709. DOI: 10.1016/j.heliyon.2024.e28282. View

10.

Lee J, Han S, Cho H, Jennings B, Gerrard B, Dean M . A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000; 19(43):4947-53. DOI: 10.1038/sj.onc.1203874. View

11.

Li S, Zhang H, Wang X, Qu Y, Duan J, Liu R . Direct targeting of HGF by miR-16 regulates proliferation and migration in gastric cancer. Tumour Biol. 2016; 37(11):15175-15183. DOI: 10.1007/s13277-016-5390-6. View

12.

Liu S, Lui W, Mok K, Wu C, Chi C . Effect of hepatocyte growth factor on cell cycle and c-met expression in human gastric cancer cells. Anticancer Res. 1997; 17(5A):3575-80. View

13.

Grojean M, Schwarz M, Schwarz J, Hassan S, von Holzen U, Zhang C . Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models. J Cell Mol Med. 2021; 25(11):4950-4961. PMC: 8178268. DOI: 10.1111/jcmm.16362. View

14.

Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, DEmidio S . Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011; 29(36):4789-95. DOI: 10.1200/JCO.2011.36.7706. View

15.

Shitara K, Kim T, Yokota T, Goto M, Satoh T, Ahn J . Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with -amplified gastric cancer. Oncotarget. 2017; 8(45):79546-79555. PMC: 5668067. DOI: 10.18632/oncotarget.18554. View

16.

Ahn S, Kim J, Kim M, Choi J, Kim W . Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer. Anticancer Res. 2017; 37(3):1127-1138. DOI: 10.21873/anticanres.11426. View

17.

Saisana M, Griffin S, May F . Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget. 2016; 7(34):54445-54462. PMC: 5342354. DOI: 10.18632/oncotarget.10642. View

18.

Feng Y, Ma P . Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer. Cancer Discov. 2012; 1(7):550-4. DOI: 10.1158/2159-8290.CD-11-0289. View

19.

Nevisi F, Yaghmaie M, Pashaiefar H, Alimoghaddam K, Iravani M, Javadi G . Correlation of HER2, MDM2, c-MYC, c-MET, and TP53 Copy Number Alterations in Circulating Tumor Cells with Tissue in Gastric Cancer Patients: A Pilot Study. Iran Biomed J. 2019; 24(1):47-53. PMC: 6900480. View

20.

Wei X, Juan Z, Min F, Nan C, Hua Z, Qing F . Recombinant immunotoxin anti-c-Met/PE38KDEL inhibits proliferation and promotes apoptosis of gastric cancer cells. J Exp Clin Cancer Res. 2011; 30:67. PMC: 3146887. DOI: 10.1186/1756-9966-30-67. View